Canaccord Genuity Reiterates a 'Buy' on Zalicus (ZLCS); Phase 1 Z944 Dosing Complete; Focus Turns To Synavive

Canaccord Genuity reiterates a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.

Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker."

"Z944 single ascending dose study shows good tolerability...Z944 has demonstrated pre--clinical efficacy in multiple inflammatory pain models."

For an analyst ratings summary and ratings history on Zalicus click here. For more ratings news on Zalicus click here.

Shares of Zalicus closed at $1.38 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
• MarineMax (HZO) PT Lowered to $35 at Stifel